Indivior’s Frank Mottola acquires 30,099 merger shares
The conversion also carried forward substantially the same award terms and vesting, except performance stock units became time-vesting restricted stock units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. (INDV), which changed its name to Supernus, Inc. in the merger, is the issuer of the 30,099 common shares SVP, Chief Tech. Ops. Officer Frank Mottola acquired on November 2, 2026. His Supernus Pharmaceuticals, Inc. common shares were exchanged at a 1.5401-for-1 ratio; he received no cash consideration other than cash in lieu of a fractional share.
The merger also assumed and converted Mottola’s outstanding options and restricted stock units into corresponding Supernus, Inc. awards. Converted awards generally retain substantially the same terms, including vesting, with option exercise prices adjusted using the exchange ratio; performance stock unit awards became time-vesting restricted stock units.
Insider Trade Summary
Other: 462,630 shares
Other
22 txns
Insider
Mottola Frank
Role
SVP, Chief Tech. Ops. Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Employee Stock Option (right to buy) F2, F3 | 21,561 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 33,882 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 26,181 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 27,721 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 46,203 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 38,502 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 30,802 | $0.00 | $0.00 |
| Other | Employee Stock Option (right to buy) F2, F3 | 20,791 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F4 | 2,887 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F5 | 3,850 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F6 | 5,197 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F7 | 4,620 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F8 | 154,010 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F9 | 5,775 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F10 | 2,618 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F9 | 2,541 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F11 | 1,078 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F12 | 1,078 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F13 | 1,078 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F12 | 1,078 | $0.00 | $0.00 |
| Other | Restricted Stock Units F2, F14 | 1,078 | $0.00 | $0.00 |
| Other | Common Stock F1 | 30,099 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 245,643 contracts (Direct);
Restricted Stock Units — 186,888 contracts (Direct);
Common Stock — 30,099 shares (Direct)
Footnotes (14)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.
- F3. The option vests in four equal annual installments beginning on the specified date.
- F4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
- F5. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
- F6. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
- F7. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
- F8. These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
- F9. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.
- F10. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2027.
- F11. These restricted stock units are settled in common stock upon vesting, which occurs on March 31, 2027.
- F12. These restricted stock units are settled in common stock upon vesting, which occurs on September 30, 2027.
- F13. These restricted stock units are settled in common stock upon vesting, which occurs on June 30, 2027.
- F14. These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.
Key Figures
Common shares acquired: 30,099 shares
Merger exchange ratio: 1.5401 shares per share
Employee stock option award: 21,561 shares; $23.87 exercise price per share
+2 more
5 metrics
Common shares acquired
30,099 shares
Frank Mottola’s merger-related acquisition on November 2, 2026
Merger exchange ratio
1.5401 shares per share
Supernus, Inc. common shares for each Supernus Pharmaceuticals common share
Employee stock option award
21,561 shares; $23.87 exercise price per share
Converted award
Employee stock option award
33,882 shares; $15.58 exercise price per share
Converted award
Restricted stock units
154,010 RSUs
40% vest upon the merger closing; 15% upon each of its first four anniversaries
Key Terms
exchange ratio, cash in lieu of a fractional share, merger-of-equals transaction, time-vesting restricted stock units
4 terms
exchange ratio financial
"multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
merger-of-equals transaction technical
"merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc."
time-vesting restricted stock units financial
"converted into time-vesting restricted stock units"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Frank Mottola’s options and RSUs in the INDV merger?
Indivior assumed and converted his outstanding equity awards into corresponding Supernus, Inc. awards. Award share amounts were multiplied by the 1.5401 exchange ratio and rounded down, while per-share option exercise prices were divided by the ratio and rounded up to the nearest whole cent. Awards generally retained substantially the same terms and vesting, except performance stock units became time-vesting RSUs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
